Cyteir Therapeutics, Inc. (CYT)
Cyteir Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lexington, MA, US. The stock last traded at $3.02, down 2.27% on the session, giving a market capitalisation of $108.7M. On trailing twelve-month figures it carries a trailing P/E of -2.42, a net margin of 0.0%. Its beta of 0.10 implies it has historically moved less than the broad market.
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.
Cyteir Therapeutics, Inc. is most often compared with the following Healthcare names: